METHODS OF USING BUTYROPHILIN ANTIBODIES FOR TREATING HIV INFECTION
The present invention relates to methods for treating individuals infected with the human immunodeficiency virus (HIV) comprising administering to the subject with an antibody to Butyrophilin that reactivates HIV from latency and/or activates CD4+ T cells.
1 . A method of treating HIV in a subject comprising the step of administering to the subject a therapeutically effective amount of an antagonist anti-Butyrophilin3A (BTN3A) antibody, wherein the antibody activates CD4 + T cells and reactivates HIV from latency.
2 . The method of claim 1 , wherein the antibody increases IFNγ production, IL-2 production or T-cell proliferation in HIV latent primary CD4+ T cells and upregulates HIV transcription in CD4+ T cells.
3 . The method of claim 1 , wherein the antibody cross competes with anti-BTN3A antibody BTN20.1 or BTN103.2.
4 . A method of reactivating HIV from latency in a subject comprising the step of administering to the subject a therapeutically effective amount of an antagonist anti-Butyrophilin3A (BTN3A) antibody, wherein the antibody reactivates HIV from latency.
5 . The method of claim 4 , wherein the antibody upregulates HIV transcription in CD4+ T cells.
6 . A method of treating HIV in a subject, said method comprising the step of administering to the subject a therapeutically effective amount of an antagonist anti-Butyrophilin3A (BTN3A) antibody.
7 . The method of claim 6 , wherein the antibody kills HIV infected T cells.
8 . A method of treating HIV in a subject comprising the step of administering to the subject a therapeutically effective amount of an antagonist anti-Butyrophilin3A (BTN3A) antibody, wherein the antibody activates CD4+ T cells.
9 . The method of claim 8 , wherein the antibody increases IFNγ production or T-cell proliferation in HIV latent primary CD4+ T cells.
10 . The method of claim 1 , wherein the anti-BTN3A antibody specifically binds to BTN3A1.
11 . The method of claim 1 , further comprising administering an anti-retroviral agent, wherein said anti-retroviral agent is selected from the group consisting of a nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, fusion inhibitor, entry inhibitor, integrase inhibitor, co-receptor antagonist, viral adsorption inhibitor, viral specific transcription inhibitor, and cyclin dependent kinase inhibitor, or a combination thereof.
12 . The method of claim 11 , wherein said anti-retroviral agent is selected from the group consisting of a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, and an integrase inhibitor, or a combination thereof.
13 . The method of claim 1 , further comprising administering a latency reversing agent.